Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
about
Endpoints, patient selection, and biomarkers in the design of clinical trials for cancer vaccinesEngineered drug resistant γδ T cells kill glioblastoma cell lines during a chemotherapy challenge: a strategy for combining chemo- and immunotherapyHumoral response to a viral glycan correlates with survival on PROSTVAC-VFEffect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.Cancer immunotherapy: sipuleucel-T and beyond.Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanismsImmunotherapy for lung cancers.Prostate cancer as a model for tumour immunotherapy.Impact of tumour volume on the potential efficacy of therapeutic vaccines.INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression.Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy.Immunotherapy for prostate cancer: recent advances, lessons learned, and areas for further research.Therapeutic cancer vaccines: the latest advancement in targeted therapy.Immunotherapy in prostate cancer: emerging strategies against a formidable foe.A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinomaStrategies used for MUC1 immunotherapy: human clinical studies.Dendritic cell-based cancer vaccination: quo vadis?Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.Immunotherapy for prostate cancer: an emerging treatment modality.Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.Vaccine-induced antibody responses in patients with carcinoma.Novel targeted agents on the horizon for castration-resistant prostate cancer.IL-13 receptor-directed cancer vaccines and immunotherapy.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Challenges and opportunities for cancer vaccines in the current NSCLC clinical scenario.Immune response to sipuleucel-T in prostate cancerTherapeutic cancer vaccines: a long and winding road to success.Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T).Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.Sipuleucel-T and immunotherapy in the treatment of prostate cancer.
P2860
Q27008070-2CD39696-B5FC-4E93-B18E-8DBA8A0F53DEQ28485036-4341EDC6-4F80-44BC-B775-A6D291778E44Q33674367-3F1741DE-178A-4057-8430-434E33E02976Q34074715-922D23C4-AC10-4E1B-B8DF-6E5F1880E0D1Q34158070-6FCA8C9D-F16A-463A-A862-87820D52093FQ34343736-20925BDD-4F28-46B0-81C8-2C99F2CA9774Q34557611-1EB936FF-CF7A-4FBA-84B9-238091219E1DQ34856875-A1B1032D-ED7C-4E29-91D5-00BF44E07221Q35027034-C928AD4D-1955-48DD-851C-2E1A50F5D3D5Q35136043-B8A6A99F-5DF7-406B-B742-881F594C55E8Q35584269-87C1817B-00E8-4960-A048-DDC77DC74B49Q36114222-79278C0B-9103-4879-A7B3-B0B58B173621Q36316871-9C169269-3804-4E09-9E95-C89C87BE001EQ36695629-E8A9C3D8-54D9-4DDC-ABCB-6B54B28DD12CQ36708792-4436452E-BF29-4C0E-A580-FFE0088A4BD5Q36777149-418A7B58-4FF7-4508-A481-1C90A446C674Q37062369-A3DEC640-A8E3-495A-A6EB-0629498D5B17Q37169042-5127AC55-3667-419A-B2BF-8A95BEA84032Q37259597-F30C88DA-3CB3-40FE-AC60-56444D29333DQ37259624-6B5D1569-AE32-4307-BB48-6050C8DB9597Q37324881-1723D956-FF39-4682-9F5B-B7BD30C21A3BQ37691634-22D01554-3963-4DCC-A17B-29B4C78C6DAEQ37729243-F0FB6E71-16C4-48B7-BABE-89C1285A6398Q37762272-341248CF-D8B6-4FA2-9C1D-590BE2007EB5Q37818294-15E37459-45F6-427D-ABF9-A10DD80A38CEQ38003478-3F0CA8E1-A032-43B0-A80D-EAF80C1BC432Q38076053-F21DE660-34C3-41B8-85AE-C33F8DF6A13AQ38143201-98278AE1-FEFF-4E8C-B767-D06F7808EAA7Q38161390-C9CAC8C6-3A9E-4759-98C3-506132F08747Q38162261-54F9DF39-CA36-411B-B0DA-33AD6167DF9CQ38720221-42E7258D-EFF3-4CD8-9308-22DF579980F0Q41593373-A06CA4A0-65F7-49A6-9507-EDB6EB394DA6Q53062915-3D73E1BD-CF70-482A-8BAE-DC7A8E4D7BF7
P2860
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@ast
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@en
type
label
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@ast
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@en
prefLabel
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@ast
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@en
P2093
P2860
P1433
P1476
Enhancing efficacy of therapeutic vaccinations by combination with other modalities.
@en
P2093
James L Gulley
Philip M Arlen
Ravi A Madan
P2860
P304
P356
10.1016/J.VACCINE.2007.04.091
P407
P478
25 Suppl 2
P577
2007-06-04T00:00:00Z